News Sentiment

KVUE sentiment intelligence

Kenvue Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Weighted score 45 Balanced news tone 52 relevant articles
Exchange NYSE United States
Sector Consumer Defensive Market context
Industry Household & Personal Products Read-through group
Latest close 19.48 Week of 10 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

73/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 9

high-authority source matches

Trend context Trend active

-1.8% over one week, +7.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Diversify Wealth Management LLC Buys New Stake in Kenvue Inc. $KVUE

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 73/100 classification
One-week reaction -1.8% Price digesting
Trend fit Trend active 7.4% over four weeks
Fair value 2.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 29
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
MarketBeat 6
Market source 6
Reuters 5
Ad Hoc News 5
simplywall.st 4
Investing.com 3
MarketWatch 2
Kavout | AI 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 12
Regulatory and legal 9
Deals and strategy 7
Capital return 3
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
MarketBeat Direct company coverage

Blackhawk Capital Partners LLC Invests $1.66 Million in Kenvue Inc. $KVUE

Blackhawk Capital Partners LLC has acquired a new stake in Kenvue Inc., purchasing 96,412 shares valued at approximately $1.66 million during the first quarter. Despite high institutional ownership and Kenvue beating recent earnings and revenue estimates, analyst sentiment remain

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 07:49
Source
MarketBeat
MarketBeat Direct company coverage

Fifth Third Bancorp Grows Position in Kenvue Inc. $KVUE

Fifth Third Bancorp significantly increased its stake in Kenvue Inc. by 167.3% in Q1 2026, holding over 600,000 shares valued at approximately $10.4 million. Kenvue reported strong quarterly results, exceeding EPS and revenue expectations, and offers a 4.4% dividend yield, though

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 07:40
Source
MarketBeat
MarketWatch Direct company coverage

Kenvue Inc. stock falls Tuesday, underperforms market

Kenvue Inc. (KVUE) shares fell by 2.44% on Tuesday, closing at $18.76. This decline occurred during a generally positive trading session where the S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the second consecutive day of losses for Kenvue stock.

Tone
Negative 20/100
Event
Market update
Published
14 Jul 2026 16:54
Source
MarketWatch
MarketBeat Direct company coverage

Calamos Advisors LLC Acquires 651,000 Shares of Kenvue Inc. $KVUE

Calamos Advisors LLC significantly increased its stake in Kenvue Inc. (NYSE:KVUE) during the first quarter of 2026, acquiring an additional 651,000 shares to bring its total to 3.351 million shares valued at approximately $57.8 million. This acquisition follows Kenvue's better-th

Tone
Positive 63/100
Event
Deals and strategy
Published
14 Jul 2026 08:23
Source
MarketBeat
GuruFocus Direct company coverage

Kenvue (KVUE) Shares Surge After Favorable Court Ruling

Kenvue (KVUE) shares rose 5% after a favorable court ruling excluded plaintiffs' expert opinions in a class action lawsuit linking prenatal Tylenol to autism or ADHD. The company plans to seek dismissal of the lawsuits, which could push its stock price to between $23 and $25 per

Tone
Positive 74/100
Event
Regulatory and legal
Published
14 Jul 2026 02:40
Source
GuruFocus
Investing.com Australia Direct company coverage

Kenvue options trading climbs to over 16,000 contracts By Investing.com

Options trading activity for Kenvue Inc. (KVUE) significantly increased to 16,298 contracts by 11:50 a.m. New York time on Monday. Call options comprised 7,912 contracts, while put options totaled 8,386 contracts. The most active contracts included the July 17, 2026 $19 put and t

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 02:04
Source
Investing.com Australia
Kenvue Direct company coverage

Second Circuit Court of Appeals Ruling

Kenvue Brands LLC, the maker of Tylenol, issued a statement regarding a Second Circuit Court of Appeals procedural ruling on acetaminophen litigation. The company emphasized that independent science shows no proven link between acetaminophen use and autism or ADHD, and highlighte

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 19:20
Source
Kenvue
Kavout | AI Direct company coverage

Kenvue's Tylenol Liability Nightmare: Appeals Court Reversal Ignites Fresh Legal Battle

A federal appeals court has reinstated hundreds of lawsuits alleging a link between prenatal Tylenol exposure and autism/ADHD, overturning a previous dismissal. This creates significant financial and reputational uncertainty for Kenvue, despite the company's insistence on Tylenol

Tone
Negative 30/100
Event
Regulatory and legal
Published
13 Jul 2026 18:38
Source
Kavout | AI
The Globe and Mail Direct company coverage

U.S. appeals court revives more than 500 lawsuits against Tylenol-maker Kenvue over autism claims

A federal appeals court has revived over 500 lawsuits against Kenvue, the maker of Tylenol, concerning claims that the painkiller causes autism and ADHD in children when used during pregnancy. The court stated that a district judge improperly excluded expert testimony from three

Tone
Negative 29/100
Event
Regulatory and legal
Published
13 Jul 2026 17:52
Source
The Globe and Mail
Moomoo Direct company coverage

Update: Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says

A federal appeals court has ruled that Kenvue, the maker of Tylenol, must face claims in multidistrict litigation alleging a link between prenatal acetaminophen use and autism spectrum disorder (ASD) or attention deficit hyperactivity disorder (ADHD). This decision overturns an e

Tone
Negative 29/100
Event
Market update
Published
13 Jul 2026 17:38
Source
Moomoo
Stocktwits Direct company coverage

KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits

Kenvue (KVUE) shares dropped after a federal appeals court revived lawsuits alleging Tylenol use during pregnancy increases the risk of autism and ADHD in children. The court overturned parts of a lower court's dismissal, allowing key expert testimonies, though Kenvue maintains e

Tone
Negative 30/100
Event
Regulatory and legal
Published
13 Jul 2026 17:09
Source
Stocktwits
MarketWatch Direct company coverage

Kenvue Inc. stock falls Monday, underperforms market

Kenvue Inc. stock (KVUE) fell 1.28% on Monday, closing at $19.23, which was below the market's performance as both the S&P 500 Index and Dow Jones Industrial Average also declined. The company's stock is now 15.92% below its 52-week high of $22.87.

Tone
Negative 30/100
Event
Market update
Published
13 Jul 2026 16:55
Source
MarketWatch
www.timothysykes.com Direct company coverage

Kenvue Inc. (KVUE) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for Kenvue Inc. (KVUE) stock, including its current price and daily performance. It also includes sections for analyst ratings and earnings information, although specific data for Kenvue Inc. is noted as unavailable. The page is part of a

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 15:38
Source
www.timothysykes.com
Reuters Direct company coverage

US appeals court revives private lawsuits linking Tylenol to autism, ADHD

A federal appeals court has revived over 500 private lawsuits against Tylenol maker Kenvue, alleging a link between Tylenol use during pregnancy and autism and ADHD in children. The 2nd U.S. Circuit Court of Appeals in Manhattan ruled that a district court judge improperly exclud

Tone
Negative 18/100
Event
Regulatory and legal
Published
13 Jul 2026 15:38
Source
Reuters
Investing.com Direct company coverage

Kenvue stock falls after court revives autism lawsuits

Kenvue Inc. shares fell 1% after a federal appeals court revived lawsuits alleging Tylenol causes autism in children whose mothers used it during pregnancy. The court overruled a lower court's decision to block cases by excluding expert testimony, remanding it for further proceed

Tone
Negative 18/100
Event
Regulatory and legal
Published
13 Jul 2026 15:30
Source
Investing.com
Bloomberg Direct company coverage

Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says

A federal appeals court has reinstated lawsuits against Kenvue Inc., the maker of Tylenol, alleging the company concealed risks that the pain reliever could cause autism in children when taken by pregnant mothers. The court ruled that a lower court improperly dismissed the cases

Tone
Negative 28/100
Event
Regulatory and legal
Published
13 Jul 2026 15:20
Source
Bloomberg
Investing.com Direct company coverage

Kenvue options trading climbs to over 16,000 contracts

Options trading activity for Kenvue Inc. (NYSE:KVUE) surpassed 16,000 contracts by Monday morning, with a near-even split between call and put options. Key activity included the July 17, 2026 $19 put and the July 17, 2026 $20 call, as well as several spread strategies and straddl

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 12:03
Source
Investing.com
ad-hoc-news.de Direct company coverage

Listerine Cool Mint by Kenvue Inc. - mouthwash staple under fresh brand owner

This article examines Listerine Cool Mint, a flagship product now under Kenvue Inc., detailing its formula, market positioning within the Listerine range, and its transition from Johnson & Johnson. It highlights the mouthwash's contribution to Kenvue's stable revenue stream, cons

Tone
Positive 73/100
Event
Earnings
Published
13 Jul 2026 11:24
Source
ad-hoc-news.de
Ad Hoc News Direct company coverage

Kenvue stock steadies as investors weigh its consumer brands

Kenvue, the maker of Tylenol and other consumer health products, is categorized as a consumer staples company, leading to a more defensive investor profile. The company's diverse portfolio across pain relief, skin health, oral care, and allergy relief means its stock performance

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 07:48
Source
Ad Hoc News
MarketBeat Direct company coverage

Kenvue (NYSE:KVUE) Rating Increased to Buy at Wall Street Zen

Kenvue (NYSE:KVUE) has received an upgrade to a "buy" rating from Wall Street Zen, though the overall analyst consensus remains a "Hold" with an average price target of $19.33. The company's shares are currently trading at $19.50, and its recent earnings exceeded expectations wit

Tone
Positive 62/100
Event
Analyst action
Published
12 Jul 2026 17:33
Source
MarketBeat
Stock Traders Daily Direct company coverage

Technical Reactions to KVUE Trends in Macro Strategies

The article provides a technical analysis of Kenvue Inc. (NASDAQ: KVUE), highlighting conflicting sentiment and suggesting choppy market conditions. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profile

Tone
Positive 64/100
Event
Market update
Published
11 Jul 2026 23:08
Source
Stock Traders Daily
MarketBeat Direct company coverage

Sumitomo Mitsui Trust Group Inc. Sells 343,749 Shares of Kenvue Inc. $KVUE

Sumitomo Mitsui Trust Group Inc. reduced its stake in Kenvue Inc. by 6.6% in the first quarter, selling 343,749 shares, though it still holds over 4.8 million shares valued at $84 million. Other institutional investors showed mixed activity, with some increasing their positions a

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 14:38
Source
MarketBeat
ad-hoc-news.de Direct company coverage

Kenvue stock holds steady as the consumer health story builds

Kenvue stock, trading on the NYSE under ISIN US49177J1025, maintains stability due to its strong consumer health portfolio and well-known household brands. Spun off from Johnson & Johnson, the company's revenue is tied to everyday health products, focusing on brand strength, pric

Tone
Positive 66/100
Event
Earnings
Published
11 Jul 2026 06:10
Source
ad-hoc-news.de
Kavout | AI Direct company coverage

Kenvue's Hidden Bullish Bet: Options Surge Amidst Acquisition and Mixed Valuation Signals

Kenvue (NYSE: KVUE) has shown a significant surge in bullish call options despite its stock largely underperforming the market and maintaining a "Hold" consensus from Wall Street analysts. This contrarian interest, combined with its ongoing integration with Kimberly-Clark and a m

Tone
Positive 67/100
Event
Deals and strategy
Published
11 Jul 2026 01:38
Source
Kavout | AI